PubMed Health⌕ Search

PubMed · 16136616

Oligonuclear 3d-4f complexes as tectons in designing supramolecular solid-state architectures: impact of the nature of linkers on the structural diversity.

Abstract

Heteronuclear cationic complexes, [LCuLn]3+ and [(LCu)2Ln]3+, were employed as nodes in designing high-nuclearity complexes and coordination polymers with a rich variety of network topologies (L is the dianion of the Schiff base resulting from the 2:1 condensation of 3-methoxysalycilaldehyde with 1,3-propanediamine). Two families of linkers have been chosen: the first consists of exo-dentate ligands bearing nitrogen-donor atoms (bipyridine (bipy), dicyanamido (dca)), whereas the second consists of exo-dentate ligands with oxygen-donor atoms (anions derived from the acetylenedicarboxylic (H2acdca), fumaric (H2fum), trimesic (H3trim), and oxalic (H2ox) acids). The ligands belonging to the first family prefer copper(II) ions, whereas the ligands from the second family interact preferentially with oxophilic rare-earth cations. The following complexes have been obtained and crystallographically characterized: [LCu(II)(OH2)Gd(III)(NO3)3] (1), [{LCu(II)Gd(III)(NO3)3}2(mu-4,4'-bipy)] (2), 1infinity[LCu(II)Gd(III)(acdca)(1.5)(H2O)2].13H2O (3), 2infinity[LCu(II)Gd(III)(fum)(1.5)(H2O)2].4H2O.C2H5OH (4), 1infinity[LCu(II)Sm(III)(H2O)(Hfum)(fum)] (5), 1infinity[LCu(II)Er(III)(H2O)2(fum)]NO3.3H2O (6), 2infinity[LCu(II)Sm(III)(fum)(1.5)(H2O)2].4H2O.C2H5OH (7), [{(LCu(II))2Sm(III)}2fum2](OH)2 (8), 1infinity[LCu(II)Gd(III)(trim)(H2O)2].H2O (9), 2infinity[{(LCu(II))2Pr(III)}(C2O4)(0.5)(dca)]dca.2H2O (10), [LCu(II)Gd(III)(ox)(H2O)3][Cr(III)(2,2'-bipy)(ox)2].9H2O (11), and [LCuGd(H2O)4{Cr(CN)6}].3H2O (12). Compound 1 is representative of the whole family of binuclear Cu(II)-Ln(III) complexes which have been used as precursors in constructing heteropolymetallic complexes. The rich variety of the resulting structures is due to several factors: 1) the nature of the donor atoms of the linkers, 2) the preference of the copper(II) ion for nitrogen atoms, 3) the oxophilicity of the lanthanides, 4) the degree of deprotonation of the polycarboxylic acids, 5) the various connectivity modes exhibited by the carboxylato groups, and 6) the stoichiometry of the final products, that is, the Cu(II)/Ln(III)/linker molar ratio. A unique cluster formed by 24 water molecules was found in crystal 11. In compounds 2, 3, 4, 9, and 11 the Cu(II)-Gd(III) exchange interaction was found to be ferromagnetic, with J values in the range of 3.53-8.96 cm(-1). Compound 12 represents a new example of a polynuclear complex containing three different paramagnetic ions. The intranode Cu(II)-Gd(III) ferromagnetic interaction is overwhelmed by the antiferromagnetic interactions occurring between the cyanobridged Gd(III) and Cr(III) ions.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ruxandra Gheorghe, Paula Cucos, Marius Andruh, Jean-Pierre Costes, Bruno Donnadieu, Sergiu Shova. 2005-12-16. Oligonuclear 3d-4f complexes as tectons in designing supramolecular solid-state architectures: impact of the nature of linkers on the structural diversity.. https://doi.org/10.1002/chem.200500321

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗